Navigation Links
Nanotechnology drug delivery shows promise for treatment of pediatric cancer
Date:12/4/2012

Wilmington, DE This month, Molecular Pharmaceutics reported promising findings from the Nemours Center for Childhood Cancer Research and the Materials Science and Engineering Department at the University of Delaware, about the potential for nanotechnology to deliver chemotherapeutic agents in a way that attacks cancer cells without harming healthy cells. To date, nanoparticle-based drug delivery approaches have been poorly developed for the treatment of childhood leukemia, which comprises 30% of childhood cancers. In the Nemours study, encapsulated dexamethasone ("dex") delivered to pre-clinical models with leukemia significantly improved quality of life and survival compared to the control receiving the unencapsulated drug.

Acute lymphoblastic leukemia (ALL) is the most common form of pediatric leukemia. Although 5-year survival rates for ALL approach 90% with available chemotherapy treatments, the deleterious side effects of the drugs, including secondary cancers and fertility, cognitive, hearing, and developmental problems, present a significant concern for survivors and their families. Dex is one of the most commonly used drugs to treat childhood leukemia and long-term systemic exposure to dex causes considerable side effects.

Studies conducted by the lead author A. K. Rajasekaran, PhD, and his team at Nemours in collaboration with Xinqiao Jia, PhD, and her team at the University of Delaware, used polymeric nanoparticles containing chemotherapeutic agents to ensure controlled delivery of drugs to cancer cells in preclinical models. "There are currently seven or eight drugs that are used for chemotherapy to treat leukemia in children," said Dr. Rajasekaran. "They are all toxic and do their job by killing rapidly dividing cells." However, he explained, these drugs don't differentiate cancer cells from other, healthy cells. "The good news is that these drugs are 80-90% effective in curing leukemia. The bad news is that many chemot
'/>"/>

Contact: Karen Bengston
kbengsto@nemours.org
302-298-7319
Nemours
Source:Eurekalert

Page: 1 2

Related biology news :

1. Purdue professor to speak before Congress about nanotechnology in brain treatment research
2. New study shows how nanotechnology can help detect disease earlier
3. Nanotechnology breakthrough could dramatically improve medical tests
4. Understanding the biological and ecological implications of safe nanotechnology
5. New study shows promise in using RNA nanotechnology to treat cancers and viral infections
6. Realizing the promise of RNA nanotechnology for new drug development
7. Mercury in water, fish detected with nanotechnology
8. European boost for DNA nanotechnology
9. Global Market for Nanotechnology to Reach $3.3 Trillion by 2018
10. Ben-Gurion U. licenses drug delivery platform for central nervous system diseases to NY biotech firm
11. Delivery of gene-therapy for heart disease boosted 100-fold; now in 100-patient trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... fish consumption advisories for expecting mothers are ineffective ... persistent organic pollutants (POPs). , The study, ... of Toronto Scarborough PhD student Matt Binnington and ... of environmental contamination, a mother,s compliance with advisories, ... influenced exposure in her children. , Their model ...
(Date:4/17/2014)... University engineer has developed a patented technique that ... devices. The same technique could help police during ... and Kay L. Theede chair in engineering and ... his research team have created a template-based system ... trunks. The distance detection method called stand-off ...
(Date:4/17/2014)... and pathogens that devastate honeybees in Europe, Asia and ... do not appear to be impacting native honeybee populations ... researchers., The invasive pests include including Nosema microsporidia ... honeybees appear to be resilient to these invasive pests, ... control pests in Europe, Asia and the United States ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Patented research remotely detects nitrogen-rich explosives 2East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3
... soon be able to make pest insects buzz off for ... all thanks to a tiny finding with enormous potential. ... Pune, India, is the senior author of a study that ... National Academy of Sciences , also called PNAS. Her work ...
... the University of Leeds have come a step closer to ... Their findings, published in the International Journal of Cancer ... to tackle other cancers should be considered as a future ... tamoxifen, that target a protein responsible for tumour growth, have ...
... , This release is available in German ... geneticists no longer dismiss out of hand his belief that ... published his book on evolution, Lamarck,s theory of transformation went ... decade, we have learned that the environment can after all ...
Cached Biology News:From protein to planes and pigskin 2From protein to planes and pigskin 3Another step toward resisting breast cancer 2Epigenetic changes don't last 2Epigenetic changes don't last 3Epigenetic changes don't last 4
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
(Date:1/14/2014)... 13, 2014 Bob Hainsey, a semiconductor ... 20 years in the industry, has joined SPIE, ... will serve as the society’s Science and Technology Strategist. ... SPIE as our Technology Strategist, further strengthening the technical ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed unknowingly to ... time period, doctors did not know that they needed to ... of vulnerable patients. In the same way, medical interns and ... transmitting herpes viruses to their patients. The CBCD explains. , ...
(Date:1/14/2014)... BioMedomics, Inc. , a Point of Care ... novel disease specific POC tests, announced today that it has ... of $690,000. The investment is from private investors and is ... of private investors has significant successful experience in early investments ...
Breaking Biology Technology:Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2
... BRISBANE, Calif., Aug. 7 InterMune, Inc. (Nasdaq: ... and President of InterMune, will present at the Canaccord Adams 29th ... 10:30 a.m. EDT. , , To access a ... may log on to the investor relations page of InterMune,s corporate ...
... YORK, Aug. 7 /PRNewswire-Asia-FirstCall/ -- , , ... --2Q09 Net Income Attributable to Controlling Interest was $13.2 million or , ... $0.17 per Diluted Share--, ... American Oriental Bioengineering, Inc. (NYSE: AOB ), ("the Company" or,"AOBO"), ...
... , , EMERYVILLE, Calif., Aug. 6 ... it has agreed to sell an aggregate of four million shares of ... share and $200 million aggregate principal amount of its 4.00% convertible senior ... the underwriters 30-day options to purchase up to an additional 600,000 shares ...
Cached Biology Technology:American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 2American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 3American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 4American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 5American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 6American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 7American Oriental Bioengineering Reports Second Quarter 2009 Financial Results 8Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes 2Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes 3
supplied with 10x reaction buffer...
... cytopathic effect inhibition assays, also known as CPE ... culture supernatents; serum from PK studies and delivery ... defined as the quantity of interferon required per ... infection by 50%. All standards used ...
... BioPrime Plus Array CGH Genomic Labeling Systems ... reproducible labeling of genomic DNA samples for ... both indirect and direct labeling formats, the ... provide a flexible solution to your genomic ...
... PBL's bioassays for interferons are cytopathic effect ... assays. Sample types include; tissue culture supernatents; ... In these assays, one unit is defined as ... reduce the cytopathic effect of viral infection by ...
Biology Products: